The use of tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) as an anticancer therapy has attracted the attention of the scientific community and created great excitement because it selectively targets cancer cells with minimal or no effects on noncancerous counterparts [3,4]. The gene discussed is TNFSF10; the disease is cancer.